Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications

Journal of Managed Care & Specialty Pharmacy
Michael HeileMichael Shannon

Abstract

Type 2 diabetes mellitus (T2DM) is associated with an increased risk of atherosclerotic cardiovascular (ASCVD) disease, which is the largest contributor to the economic burden of diabetes. Minimization of disease morbidity through comprehensive management of ASCVD risk factors, including but not limited to hyperglycemia, is a key goal of T2DM therapy. Emerging evidence with some glucagon-like peptide-1 receptor agonists (GLP-1 RAs) points to beneficial effects across a range of atherosclerotic risk factors and possible improvement of some cardiovascular outcomes independent of these effects. Given these benefits, there has been substantial interest in evaluating the cardiovascular safety of GLP-1 RAs as well as their potential to reduce the risk of major adverse cardiac events (MACE). Following the superior clinical outcome with the once-daily GLP-1 RA liraglutide (Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results [LEADER]), this review examines and summarizes the effects of once-weekly GLP-1 RAs, including exenatide extended release (ER), dulaglutide, and semaglutide, on reducing cardiovascular events in patients with T2DM. A phase 3 cardiovascular outcomes trial (EXSCEL) of exenatide ER f...Continue Reading

References

Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Feb 20, 2007·Pharmacology & Therapeutics·Máire E Doyle, Josephine M Egan
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Mar 11, 2010·Diabetes Care·John B BuseUNKNOWN DURATION-1 Study Group
Apr 16, 2014·The Lancet. Diabetes & Endocrinology·Michaela DiamantMichael E Trautmann
May 24, 2014·Circulation Research·John R Ussher, Daniel J Drucker
May 27, 2015·Journal of Managed Care & Specialty Pharmacy·Jennifer S KorsnesDebanjali Mitra
Jul 21, 2015·Journal of Medical Economics·Stephen S JohnstonIftekhar Kalsekar
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Mar 21, 2016·American Heart Journal·Rury R HolmanAdrian F Hernandez
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Jan 20, 2017·Expert Opinion on Drug Safety·Niels B DalsgaardFilip K Knop
Apr 25, 2017·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Philip A LevinSeoyoung C Kim
Apr 27, 2017·Annals of Pediatric Endocrinology & Metabolism·Seungah Lee, Dong Yun Lee
Jun 24, 2017·Current Medical Research and Opinion·Kathryn FitchHelen Blumen
Sep 15, 2017·The New England Journal of Medicine·Rury R HolmanUNKNOWN EXSCEL Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.